(Bloomberg) --

Pfizer Inc. and Moderna Inc. have increased the prices of their Covid-19 vaccines in the latest supply contracts with the European Union, the Financial Times reported.

The price rises come as the bloc deals with supply disruptions and side-effect concerns from other shots, the FT said. The terms of the deals -- struck this year and covering up to 2.1 billion shots until 2023 -- were renegotiated after Phase 3 clinical trial data showed vaccines from the two companies are more effective than some rivals, it said.

The new price for a Pfizer shot is 19.50 euros ($23.15), up from 15.50 euros previously, the newspaper said, citing portions of contracts it had seen. A Moderna jab increases to $25.50 a dose, it said.

Pfizer declined to comment to the FT on pricing. Moderna did not respond to the FT’s request for comment on EU pricing.

©2021 Bloomberg L.P.